CR will have to wait til July (new financial year). Any Cr before then will have to get SH approval which is unlikely to get.
But they could have convertible note, debt funding, royalty or deals in the meantime.
Best scenario is an investment/deal from/with big pharma. Con note or debt funding will not be seen as very positive, IMO.
Ann: March 2025 Quarterly Activities Report & Appendix 4C, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.020(6.90%) |
Mkt cap ! $120.7M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 28.0¢ | $97.62K | 331.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 74197 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 54675 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| PAR (ASX) Chart |